

Case Report

Diabetic Foot in Algeria Illustration IV – Clinical Case Report

Nadia Boudjenah

General Surgeon, Diabetic Foot Surgeon, Diabetic Foot center, Algiers, Algeria.

Corresponding Author: Nadia Boudjenah, General Surgeon, Diabetic Foot Surgeon, Diabetic Foot center, Algiers, Algeria.

Received date: July 01, 2022; Accepted date: July 11, 2022; Published date: July 18, 2022

Citation: Nadia Boudjenah (2022). Diabetic Foot in Algeria Illustration IV – Clinical Case Report. J. Archives of Medical Case Reports and Case Study, 6(2); **DOI:**10.31579/2692-9392/137

Copyright: © 2022 Jiancheng Zeng, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

It seemed interesting to us to share this observation because it reflects our management of the diabetic patient with a wound and suffering from a severe disabling Neuropathy.

Our clinical case today is a 55-year-old male. A patient with type 2 diabetes, on insulin therapy and oral anti-diabetics and being treated for high blood pressure. He came to our consultation on August 05, 2020, with an infection of the right foot, of which the starting point is the second and third toes. These ones being ischemic

Key words: diabetic foot; general surgeon; neuropathy

Introduction

It seemed interesting to us to share this observation because it reflects our management of the diabetic patient with a wound and suffering from a severe disabling Neuropathy.

Our clinical case today is a 55-year-old male. A patient with type 2 diabetes, on insulin therapy and oral anti-diabetics and being treated for high blood pressure. He came to our consultation on August 05, 2020, with an infection of the right foot, of which the starting point is the second and third toes. These ones being ischemic. *Picture below*.



First visit: AUGUST 05, 2020

We also found, apart from foot damage, tingling and unbearable disabling pain of a neurological type on the four limbs with a predominance in the lower limbs.

This patient seemed asleep to us because of heavy medication. He was not feverish and his blood sugar on arrival was 3 g/l. We also found a moderate diastasis of the rectus abdominis.

To assess the patient's condition, we asked for several tests to be done as quickly as possible:

- blood test of which the results below show the following: an infection, an anémia, vit D3 insufficiency, hyperthyroidism, Hb1Ac at 10.1% and minor disturbances in liver function.

Dr. B. HAMMADI

Médecin biologiste Ancien Praticien Consultant des hôpitaux de Paris Biochimie, Hématologie, Parasitologie, Microbiologie, Immunologie, Hormonologie Adresse : 04, Avenue Colonel Lotfi B.E.O, Alger - Téléphone : 021 97.86.30 Mobile : 05 40 97 32 88



Médecin traitant :



Alger le, 06/08/2020 Nº: 5051

BIOCHIMIE

	ARCHITECT	ABBOTT		
	Résultats	Unités	Valeurs de référence	Antériorité
CALCIUM SANGUIN (CA)	84	mg∕L	80 - 105	
C- REACTIVE PROTEINE (CRP) Résultat vérifié.	90	mg <i>i</i> l	< 6	
CHOLESTEROL TOTAL	2.20	g <i>i</i> l	1.50 - 2.50	
HDL- CHOLESTEROL	0.61	g <i>i</i> l	sup à 0.35	
CREATININE SANGUINE (CREATINEMIE)	13	mg <i>i</i> l	5 - 14	
GLUCOSE SANGUIN (GLYCEMIE)	. 1.77	gA	0.60 - 1.10	
PHOSPHORE SANGUIN	40	mg <i>i</i> l	25 - 50	
TRIGLY CERIDES	1.20	gA	0.40 - 1.60	
UREE SANGUINE (UREMIE)	0.46	gA	0.15 - 0.50	
HEMOGLOBINE GLYCOSYLEE Sujet non diabétique : 4.2 - 6.20 % Sujet diabétique équilibré : < 7 % Sujet diabétique mal équilibré :> 7.5 %	. 10.1	¥i.	4.2 - 6.20	
LDL- CHOLESTEROL	1.35	g/	infà 1.60	
25 hydroxyvitamine D2/D3		ng <i>i</i> mi		
Carence			inf 20	
Insuffisance	22		20 - 29	
Taux recommandés			30 - 100	

Horaires d'ouvertures : Samedi à Jeudi de 08h00 à 17h00

Page 1/4

Dr. B. HAMMADI Médecin biologiste

Ancien Praticien Consultant des hôpitaux de Paris Biochimie, Hématologie, Parasitologie, Microbiologie, Immunologie, Hormonologie Adresse : 04, Avenue Colonel Lotfi B.E.O, Alger - Téléphone : 021 97.86.30 Mobile : 05 40 97 32 88



Nom : A Prénom : A Prénom : A Age : 55 ans

Médecin traitant :

HEMATOLOGIE

Nº: 5051

	SYSMEX			
	Résultats	Unités	Valeurs de référence	Antériorités
NUMERATION-FORMULE SANGUINE (NFS)				
GLOBULES BLANCS	10600	MM3	4000 - 10000	
GLOBULES ROUGES	5.18	million/MM3	42-57	
HEMOGLOBINE	10.0	G/LOOML	14.0 - 17	
HEMATOCRITE	29.5	96	40 - 52	
V.G.M	57.0	μ3	80 - 95	
Т.G.М.Н	19.3	PG	28 - 32	
С.С.М.Н	33.8	g/dl	30 - 35	
PLAQUETTES	229	mille/MM3	150 - 450	
EQUILIBRE LEUCOCYTAIRE				
POLYNUCLEAIRE NEUTROPHILE	70.0	96	47 - 70	
POLYNUCLEAIRE EOSINOPHILE	3.0	96	01-05	
POLYNUCLEAIRE BASOPHILE	0.7	96	0 - 01	
LYMPHOCYTES	21.5	96	20 - 40	
MONOCYTES	4.8	96	3 - 7	

HORMONOLOGIE

	ARCHITECT Résultats	Unités	Valeurs de référence	Antériorités
FREE T4 (FT4)	13.05	ртоlЛ	0.300 - 4.500	
FREE T3 (FT3)	3.14	pmol/l	2 00 - 4.20	
THYREOSTIMULINE (TSH 3eme GEN)	2.420	µ UVml	0.300 - 4.500	
Ac ANTI Tg	134.06	UML	< 95	

Horaires d'ouvertures : Samedi à Jeudi de 08h00 à 17h00

Page 2/4

Dr. B. HAMMADI Médecin biologiste

Ancien Praticien Consultant des hôpitaux de Paris Biochimie, Hématologie, Parasitologie, Microbiologie, Immunologie, Hormonologie Adresse : 04, Avenue Colonel Lotfi B.E.O, Alger - Téléphone : 021 97.86.30 Mobile : 05 40 97 32 88



Alger le, 06/08/2020 Nº: 5051

Nom : Prénom : Aller Age : 55 ans

Médecin traitant :

Ac ANTITPO	24.26	UI/mL	< 30.0
P.S.A TOTAL	1.680	ng <i>i</i> mi	< 4

HEMOSTASE

	STAGO			
	Résultats	Unités	Valeurs de référence	Antériorités
TAUX DE PROTHROMBINE (TP)				
TEMPS DE QUICK	12.5	Sec	11 - 14	
TAUX DE PROTHROMBINE	100	96	70 - 100	
I.N.R	1.0		1 - 2	

ENZYMOLOGIE

	ARCHITECT Résultats	ABBOTT Unités	Valeurs de référence	Antériorités
BILIRUBINE				
BILIRUBINE TOTALE	10	mg A.	0 - 10	
BILIRUBINE DIRECTE	04	mg A.	0 - 2.5	
BILIRUBINE INDIRECTE	06	mg/L	0 - 7.5	
GAMMA G.T ENZYME SERIQUE	. 80	UI/L	11-50	
TRANSAMINASES				
SGOT/ASAT	20	UI/L	inf à 38	
SGPT/ALAT	21	UI/L	infà40	
PHOSPHATASES AL CALINES (PAL)	226	UI/L	98 - 279	

MICROBIOLOGIE

Unités Valeurs de référence

e Antériorités

Horaires d'ouvertures : Samedi à Jeudi de 08h00 à 17h00

Résultats

Page 3/4

⁻ bacteriological study by swab of the wound which has revealed a klebsiella sp infection sensitive to imipenem.

Dr. B. HAMMADI

Médecin biologiste

Ancien Praticien Consultant des hôpitaux de Paris Biochimie, Hématologie, Parasitologie, Microbiologie, Immunologie, Hormonologie Adresse : 04, Avenue Colonel Lotfi B.E.O, Alger - Téléphone : 021 97.86.30 Mobile : 05 40 97 32 88



Alger le, 06/08/2020 Nº: 5051

Nom : A	
Prénom :	
Age : 55 ans	
Médecin trai	tant :

ECB DIVERS

Type de prelevement:	Plaie
BACTERIOLOGIE	
Aspect	Trouble
Hematies	Absence
Leucocytes	+
CULTURE	POSITIVE
Germes	klebsiella sp
MYCOLOGIE	NEGATIF
levures	NEGATIF
ANTIBIOGRAMME	
PRISTINAMYCINE	RESISTANT
CIPROFLOXACIN	RESISTANT
IMIPENEM	SENSIBLE
GENTAMICIN	SENSIBLE
AUGMENTIN	SENSIBLE
CLOXACILLIN	RESISTANT
AMPICILLINE	SENSIBLE
CEFALEXIN	RESISTANT
ACIDE FUCIDIQUE	RESISTANT

- An arterial and venous Echodoppler revealed an atheromatous arterial disease with bilateral thrombosis of the two Pedal Arteries, the right being almost complete. There are no venous complications.

CABINET MÉDICAL CARDIOLOGIE

Dr AIT BELKACEM Samir Spécialiste des Maladies du cœur et des Vaisseaux

CARDIOLOGUE

ECG - Echodoppler Couleur Cardiaque et Vasculaire - MAPA Holter ECG - Epreuve d'Effort



الدكتور آيت بلقا سم سمير أخصائي في أمراض القلب و الأوع**ية 03 lot Vincent - Bouzaréah** ALGER (face à la BNA) Tél. /Fax : 021 90 97 23 Mob : 0770 33 84 18

-RENDU D'ECHODPPLER ARTERIEL DE MI

NOM : PRENOM : Age/né(e) : 1965 Date : 05/08/20	-			
	NOM :	PRENOM :	Age/né(e):1965	Date : 05/08/20

<u>Demandé par DR BOUDJENAH</u>

<u>MEMBRE INFRIEUR GAUCHE :</u>

*ARTERE FEMORALE COMMUNE: VEL=cm/s.

-Paroi épaissi ; Les courbes de vélocités sont correcte

*ARTERE FEMORALE PROFO NDE : VEL=cm/s.

Paroi épaissi ; Les courbes de vélocités sont correcte

*ARTERE FEMORALE SUPERFICIELLE : VEL=cm/s.

- Paroi épaissi et le flux est correcte

*ARTERE POPLITEE : VEL=cm/s.

-paroi peu épaisse, à lumière vasculaire libre .Les courbes de vélocités sont correcte

*ARTERE TIBIALE POSTERIEURE : VEL=cm/s.

- Paroi épaissi avec un flux correcte

*ARTERE TIBIALE ANTERIEURE : VEL=cm/s.

- - Paroi épaissi , Les courbes de vélocités sont correcte

*ARTERE PEDIEUSE: VEL=cm/s.

- Paroi épaissi avec une thrombose incomplète distale segmentaire

• MEMBRE INFRIEUR DROIT :

-Mêmes données hémodynamiques et morphologiques qu'à gauche même:

*ARTERE PEDIEUSE :VEL=cm/s.

- Paroi épaissi avec thrombose quasi-complète

CONCLUSION:

. Artériopathie athéromateuse avec thrombose bilatérale des deux A PED

Merci

DR AIT BELKACEM. S.



Dr AIT BELKACEM Samir Spécialiste des Maladies du cœur et des Vaisseaux

CARDIOLOGUE ECG - Echodoppler Couleur Cardiaque et Vasculaire - MAPA Holter ECG - Epreuve d'Effort



SPÉCIALISÉ EN

الدكتور آيت بلقا سم سمير ألحص *ألي في أمر*اض القلب و الأوعية 03 lot Vincent - Bouzaréah ALGER (face à la BNA) Tél. /Fax : 021 90 97 23 Mob. : 0770 33 84 18

-COMPTE-RENDU D'ECHODOPPLER VEINEUX DES MI

NOM :	PRENOM	Age/nee:1965	Date : 05/08/20
-------	--------	--------------	-----------------

Demandé par Dr Boudjenah

	MEMBRE INFERIEUR GAUCHE:
	-RESEAU VEINEUX PROFOND :
	-VEINE FEMORALE COMMUNE:
LE NIVEAU	Facilement compressible, lumière libre et flux spontané normal.
PROXIMALE	-VEINE FEMORALE SUPERFICIELLE :
TROMINIZE	-Compressible sur tout son étendu, perméable, sans image intra – luminale visible.
	-VEINE POPLITE :
	-Paroi souple, pas d'image intra-luminale visible, drainant normalement les veines d'amont.
LE NIVEAU	- <u>LES VEINES JAMBIERES : (veines tibiale postérieur et péronière)</u>
SURAL:	Paraissent perméable de dimensions normales et continentes.
	-LES VEINES MUSCULAIRES :(veines jumelles et soléaire)
	Paraissent perméable de dimensions normales et continentes.
	-RESEAU VEINEUX SUPERFICIEL :
-VEINE SAPI	HENE INTERNE :
-Légèrement	dilatée, perméable, et sans signes d'incontinence ostiale et tronculaire.
-VEINE SAPI	HENE EXTERNE :
-Dimensions r	iormales perméable, et continente.

MEMBRE INFERIEUR DROIT :

Mêmes données hémodynamiques et morphologiques qu'à gh -CONCLUSION:

-Examen ECHODOPPLER VEINEUX DES MI trouve des axes veineux profonds perméables, facilement dépressibles, sans image intra luminale visible, non dilaté, a paroi souple, avec des courbes de flux correctes.

-Le réseau superficiel est perméable et continent.

-présence de varicosites, varices réticulaires mal systématisées bilatérale de taille variable, **non thrombosée**

Avec contraste spontanée **intense** dans RESEAU VEINEUX PROFOND ++ Intérêt de prendre l'Aspégic

-PAS DE THROMBOSE VEINEUSE PROFONDE

Confraternellement

- A PeriCam, a microcirculation exam:



- A Périflux 6000, a macrocirculation exam, has revealed that this patient has 25 mmHg at the level of the right ankle, which testifies to a critical ischemia of the right limb and suggesting a difficulty in healing.

12/08/2020	Patient		^{ID} h			
en 49-00117-04 - ABI TE	BI TCP Opérateur dr boudjenah		Sce.			
Notes d'exar	nen					
Historique m	édical					
meur Non	Maladie ca	rdiaque non				
abètique Oui	Maladie pu	Ilmonaire non				
uropathie Oui	Hypertensi	ion oui				
	Devileur	Distant				
nuch Oui	Non	Plaies	Pouls pal	pable		
oite Oui	Non	Oui	oui			
olte Oui	Non pressions périphé	oui	oui oui Valet	urs de réf	érence	S
<i>Examen des</i>	Non pressions périphé	oui	oui oui Valet ABI	urs de réf	érence: 0,91 - 1,	s ,4(
Reference	Non pressions périphé	oui riques	oui oui Valet ABI TBI	urs de réf	érence: 0,91 - 1, > 0,70	s ,4(
Reference (Bras GAUCHE) M mmHg 128	Non pressions périphé	Oui riques	oui oui Vale ABI TBI Pressio	urs de réfi n Cheville	érence: 0,91 - 1, > 0,70 > 70 mn	s ,4(
Reference (Bras GAUCHE) M mmHg 128	Non pressions périphé	Oui riques	oui oui Vale ABI TBI Pressio Pressio	urs de réf n Cheville n Orteil	érence: 0,91 - 1, > 0,70 > 70 mn > 50 mn	s ,4(
Cheville	Non pressions périphé DROITE	Oui riques	oui oui Vale ABI TBI Pressio Pressio	urs de réf n Cheville n Orteil e GAUCH	érence: 0,91 - 1, > 0,70 > 70 mn > 50 mn	s ,4(nH
Cheville	Non pressions périphé DROITE 2 M	Oui	OUI OUI Vale ABI TBI Pressio Pressio Cheville (Bras GAUCHE)	urs de réfi n Cheville n Orteil e GAUCH 2	érence: 0,91 - 1, > 0,70 > 70 mn > 50 mn E	s ,40 nH
Examen des Reference (Bras GAUCHE) M mmHg 128 Cheville (Bras GAUCHE) mmHg	Non Pressions périphé DROITE 2 M 132 132	Oui riques	OUI OUI OUI Valet ABI TBI Pressio Pressio Pressio Chevilla (Bras GAUCHE) mmHg	urs de réf n Cheville n Orteil e GAUCH 2	érence: 0,91 - 1, > 0,70 > 70 mn > 50 mn E	s ,4(
Image: Cheville Cheville (Bras GAUCHE) M 128	Non pressions périphé DROITE 2 M 132 132 1,03 1,03	Oui	OUI OUI OUI Vale ABI TBI Pressio Pressio Chevillo (Bras GAUCHE) MmHg ABI	urs de réfr n Cheville n Orteil e GAUCH 2	érence: 0,91 - 1, > 0,70 > 70 mm > 50 mm E 182 1,42	s ,40 nH
olte Oui Examen des Reference (Bras GAUCHE) M mmHg 128 Cheville (Bras GAUCHE) mmHg ABI	Non pressions périphé DROITE 2 M 132 132 1,03 1,03	Oui	OUI OUI OUI Vale ABI TBI Pressio Pressio Pressio (Bras GAUCHE) MmHg ABI	urs de réfi n Cheville n Orteil e GAUCH 2	érence: 0,91 - 1, > 0,70 > 70 mn > 50 mn E 182 1,42	s ,4(nH
Oute Oui Examen des Reference (Bras GAUCHE) MmHg 128 Cheville (Bras GAUCHE) mmHg ABI Orteil E	Non pressions périphé DROITE 2 M 132 132 1,03 1,03 DROIT	Oui	oui oui Vale ABI TBI Pressio Pressio (Bras GAUCHE) mmHg ABI	urs de réfo n Cheville n Orteil e GAUCH 2 GAUCHE	érence: 0,91 - 1, > 0,70 > 70 mn > 50 mn E 182 1,42	s ,40 nH nH
Olte Oui Examen des Reference (Bras GAUCHE) MmHg 128 Cheville (Bras GAUCHE) mmHg ABI Orteil I (Bras GAUCHE)	Non Pressions périphé 2 M 132 132 1,03 1,03 DROIT 1 M	Oui	OUI OUI OUI OUI Vale ABI TBI Pressio Pressio Pressio Chevilla (Bras GAUCHE) MmHg ABI	urs de réfi n Cheville n Orteil e GAUCH 2 GAUCHE	érence: 0,91 - 1, > 0,70 > 70 mn > 50 mn E 182 1,42	s 40 nH 1
Reference (Bras GAUCHE) MmHg 128	Non pressions périphé 2 M 132 132 1,03 1,03	Oui	OUI OUI OUI OUI Valed ABI TBI Pressio Pressio Pressio Chevilla (Bras GAUCHE) mmHg ABI	urs de réfo n Cheville n Orteil e GAUCH 2 GAUCHE 1	érence: 0,91 - 1, > 0,70 > 70 mn > 50 mn E 182 1,42	s ,40 nH 1

1 (4)





An ENMG revealed a severe and diffuse demyelinating Neuropathy in the four limbs, predominating in the lower limbs, as evidenced by the complement we requested following an ENMG of the lower limbs carried out on 06/22/2020.

CENTRE D EXPLORATIONS FONCTIONNELLES DU SYSTEME NERVEUX ET DU MUSCLE Dr Y. IDIR Spécialiste en Neurophysiologie Clinique	CONCLUSION Cette exploration ENMG révèle des signer électrophysiologiques en faveur d'une <u>Neuropathie</u> sensitive et motrice, essentiellement démyélinisante asses sévère et diffuse aux extrémités des membres supérieurs
08, Boulevard du Commandiant Adderrahmane MIRA B E O Alger E mail i dir yaz@gmail.com Compte Rendu d'ENMG	pouvant entrer dans le cadre des completentes neurologiques périphériques du <u>Diabète</u> . En compléments de l'ENMG des membres inférieures cette atteinte est donc assez sévère et diffuse aux membres.
Patient (e) : Date d'examen le : 11 Août 2020	Remerciements pour votre confiance. Confraternellement
Assurance : Code : 08/20EMG 24 Médecin Traitant : Dr BOUDJENAH / Chirurgien.	Neurophysiologie Clinique Neurophysiologie Clinique Neurophysiologie Clinique
System9(US ReportAbderratimatic Amiri (03/03/1985)	1 SystemPLUS Report Abderrahmane Amiri (03/03/1965) វើសារដើ

In a didactic concern, we will detail our support chapter by chapter.

In relation to diabetes:

- the *HbA1c* level was 10,1%. We have started a controlled diet eradicating all sugar intake. It is based on the ingestion of vegetables apart from potatoes and, in the absence of renal insufficiency, on moderate protein intake accompanied by a lot of drinking.
- Controlled physical activity.

This support made it possible to reduce and even stop the insulin supply and treat the patient only by oral anti-diabetics:

His *HbA1c* control after 12 months was at 6,4% and was very stable.

Other anomalies noted during the exams have been corrected.

Regarding the Diabetic Neuropathy:

- the patient's altered state of consciousness, which led to proven stupefaction, is due to a massive intake of Lyrica 50--ten tablets per day. We asked the patient to reduce the doses gradually. However, he did not listen to us and wanted to quickly get rid of this addiction abruptly stopping his treatment. This was followed by a major depressive state with unbearable pain in the lower limbs and above all cutaneous hyperesthesia prohibiting the slightest contact. - Moreover, aggravating his condition, this patient no longer had sexual intercourse due to a lack of erection and ejaculation. He was seriously perturbated psychologically.

Once the problems of Neuropathy with erectile dysfunction were clearly identified, we offered the patient a psychiatric consultation which he received without conviction because, to help him get rid of his addiction, he was offered other medications like Lyrica 50, which he categorically refused.

We therefore took him back to treat his Neuropathy by carrying out a full weekly Carbomedtherapy (Carbon Dioxide Therapy) sessions for six months, then every two weeks thereafter. These sessions were painful at the beginning, but the important motivation of the patient helped him cope very well with it.

Currently and after 18 months of care, this patient who was on sick leave has returned to service (he holds a position of responsibility). He no longer feels pain, practices sports regularly, has a fulfilling sex life and above all, he is no longer addicted to any product.

Periodic checks were carried out and showed improvement in vascular and neurological conditions.

- PeriCam exam: control after 4 weeks from 1st scan.



Périflux 6000 exam shows that the patient has moved out of the danger zone.

-

04/05/20	122	Patient		ID	н		
nen 49-0011	7-04 - ABI TBI TCP	Opérateur DR BOUDJENAH	1	Sce.			
Notes	s d'examen						
Histo	rique médi	cal					
umeur	Non	Maladie ca	rdiaque NON				
iabètique	Oui	Maladie pu	Imonaire NON				
europathie	Oui	Hypertensi	on OUI				
Doul	eur à la marche	Douleur au repos	Plaies	Poul	s palpable		
auch Non		Non	Non	OUL	o pulpuble		
Exam	nen des pre	Non Ssions périphé	Non	OUI			
Proite Non Exam Refere	nen des pre	Non ssions périphé	Non	OUI	Valeurs de réf	férenc 0,91 -	es 1,4
Refere	ence	Non ssions périphé	Non		Valeurs de réf 81 81	férenc 0,91 - > 0,70	es 1,4
Refere (Bras DROI mmHg	ence	Non ssions périphé	Non		Valeurs de réf 81 81 ession Cheville ession Orteil	férenc 0,91 - > 0,70 > 70 m > 50 m	es 1,4 nmF
Refere (Bras DROI mmHg	ence T) M 129 Cheville DROI	Non ssions périphé	Non	OUI OUI AE TB Pro Pro	Valeurs de réf 81 ession Cheville ession Orteil	férenc 0,91 - > 0,70 > 70 m > 50 m	es 1,4 1mH
Refere (Bras DROI (Bras DROI	ence T) M 129 Cheville DROI T) 1	Non Ssions périphé TE	Non	OUI OUI AE TB Pro Pro Che (Bras DROIT)	Valeurs de réf 81 81 ession Cheville ession Orteil eville GAUCHI 1	férenc 0,91 - > 0,70 > 70 m > 50 m	es 1,40 nmH nmH
Refere (Bras DROI (Bras DROI mmHg	nen des pres ence T) M 129 Cheville DROI T) 1	Non SSIONS PÉRIPHÉ	Non	OUI OUI AE TB Pro Pro (Bras DROIT) mmHg	Valeurs de réf 81 81 ession Cheville ession Orteil eville GAUCHI	férenc: 0,91 - > 0,70 > 70 m > 50 m E 119	es 1,4 nmH nmH
Conte Non Exam (Bras DROI mmHg (Bras DROI mmHg ABI	ence T M 129 Cheville DROI	Non SSIONS PÉRIPHÉ TE M 104 104 0,81 0,81	Non	OUI OUI AE TB Pro Pro (Bras DROIT) mmHg ABI	Valeurs de réf 81 ession Cheville ession Orteil eville GAUCHI 1	férenc 0,91 - > 0,70 > 70 m > 50 m E 119 0,92	es 1,4 nmł nmł 1 1 0,1
Refere (Bras DROI mmHg (Bras DROI mmHg ABI	ence T M 129 Cheville DROI T) 1	Non SSIONS PÉRIPHÉ TE M 104 104 0,81 0,81	Non	OUI OUI AE TB Pro Pro (Bras DROIT) (Bras DROIT) MmHg ABI I	Valeurs de réf 81 ession Cheville ession Orteil eville GAUCHI 1	férenc 0,91 - > 0,70 > 70 m > 50 m E 119 0,92	es 1,4 nmF nmF 1 0,5
Refere (Bras DROI mmHg (Bras DROI mmHg ABI	ence T) M 129 Cheville DROI T) 1 Cheville DROI	Non Ssions périphé 104 104 0,81 0,81	Non	OUI OUI AE TB Pro Pro (Bras DROIT) mmHg ABI	Valeurs de réf 31 81 ession Cheville ession Orteil 1 1 1	férenc 0,91 - > 0,70 > 70 m > 50 m E 119 0,92	es 1,44 nmF nmF 0,5
(Bras DROI MmHg (Bras DROI (Bras DROI (Bras DROI (Bras DROI	ence T) M 129 Cheville DROI T) 1 Orteil DROI T) 1	Non SSIONS PÉRIPHÉ TE M 104 104 0.81 0,81	Non	OUI OUI AE TB Pro Pro Pro Che Che Che Che Che Che Che Che Che Che	Valeurs de réf 31 81 ession Cheville ession Orteil 1 teil GAUCHE 1	férenc 0,91 - > 0,70 > 70 m > 50 m E 119 0,92	es 1,40 nmH nmH 11 0,9
(Bras DROI (Bras DROI mmHg (Bras DROI mmHg (Bras DROI mmHg	ence T M 129 Cheville DROI T 1 Orteil DROIT T 1 1	Non Ssions périphé M 104 0,81 0,81 0,81	Non	OUI OUI AE TB Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro	Valeurs de réf 81 81 ession Cheville ession Orteil 1 1 teil GAUCHE 1	férenc: 0,91 - > 0,70 > 70 m > 50 m E 119 0,92	es 1,40 mmH mmH 11 0,9 M 12

Enregistré avec le PeriFlux 6000

1 (4)







- The most recent ENMG shows a marked improvement and clinically confirmed by the patient.

DU SYSTEME NERVEUX ET DU MUSCLE	CONCLUSION	
Dr Y. IDIR Spécialiste en Neurophysiologie Clinique	Ce Comparativement à l'exploration du 07/04/2021 l'ENMG de ce jour révèle une relative amélioration de la	
Boulevard du Commandant Tél : 023.17.08.10 ddarahmane MIRA. B.E.O.Alger mob : 0555.93.72.64 mail : idir.yaz@gmail.com Mob : 0770.20.06.77	 conduction des nerfs moteurs et sensitifs. Il persiste, cependant, des signes en faveur d'une <u>Neuropathie</u> sensitive et motrice, essentiellement démyélinisante, diffuse aux extrémités des 4 membres. 	
Compte Rendu d'ENMG		
	Remerciements pour votre confiance.	
	Confraternellement.	
Patient (e) :		
Data dayaman la . 11/05/2022	his wette	
Date d'examen le : 11/05/2022 Motif de la demande : contrôle (DNID)	Dr. Dr. Specialiste en	

However, medical support for the patient is not over. As we have described it, it can last up to 36 months.

Regarding the wound:

- 1. During the first week, on arrival:
- A As local treatment:
 - We recommend foot baths with a mixture of water and hydrogen peroxide daily.
 - Every day, we cover the wound with a cream Belcic*, and complete with a light dressing which is made by compresses and gauze bands.
 - The rehydration of the feet is ensured by Coconut*, a locally made cream.

- For mycosis, we use Belmyc* drops and Belmyc spray*.
- B As medical treatment after bacteriological tests:
 - Antibiotic therapy: Imipenem for 1 week
- Anticoagulants: Aspegic 100, Plavix and Lovenox.
- 2. During 2nd week:
- local treatment + Maggot Therapy.
- Depending on the results of the antibiogram, we put the patient on Ciprofloxacin and Metronidazole, and we continue the anticoagulants.
- Once the necrosis had been eliminated, we used Altrazeal powder* once a week to accentuate the budding allowing complete healing after 15 weeks' time. Figure below:



First visit: AUGUST 05, 2020



Maggot Therapy: AUGUST 19, 2020



OCTOBER 14, 2020



Healed: NOVEMBER 18, 2020

-Carbomedtherapy (Carbon Dioxide Therapy): 1st session on the first day focusing only on the lower limbs. After obtaining the ENMG results, we started the treatment of the Peripheral Diabetic Neuropathy, therefore upper limbs, and lower limbs.

Diabetes is the main cause of Neuropathy worldwide. More than 50% of diabetics worldwide, whether type 1 or 2, are affected.

Neuropathy is a consequence of microcirculatory damage in diabetics. The damage caused destroys the nerves. It is caused by the aggression of hyperglycemia. Treating Diabetic Neuropathy is a big challenge. As an outpatient clinic specializing in the treatment of diabetic foot, over 95% of our patients have Neuropathy.

Clinical examination of the patient finds the classic Neuropathy signs: tingling, numbness, cramping, pain, electric shock, loss of especially plantar sensitivity, sensitivity disorder otherwise. In the upper limbs, we look for lesions of the carpal tunnel, as well as lesions of the tarsal canal for the lower limbs. In addition, we note the degree of dryness of hyperkeratosis, the existence of a diabetic foot ulcer or a Charcot foot. Amyotrophy is correlated with the severity of the disorder. It can cause paralysis. We have noticed that the first neurological damage is the Oto-Rhino Laryngitis sphere--we noticed a decrease in hearing. The diastasis-recti is a late sign and expresses the severity of Neuropathy. The diagnosis is confirmed by the realization of an ENMG of the four limbs.

So, for this fact and to relieve our patients, we first start by stabilizing the diabetes:

• The HbA1c should be around 6, which we get easily by enforcing strict diet, hydration, physical activities and above all, psychological support - awareness is an important factor.

• We correct the usual Vitamin D3 deficits after dosing.

- We stop all analgesic treatments because we see it as an overwhelming of our patients who reduce considerably their activities, gain weight, unbalance their diabetes to finally worsen their Neuropathy to the point of destroying everything and no longer feeling anything--Paralysis sets in.
- We offer Carbomedtherapy (Carbon Dioxide Therapy) treatment sessions.

So, what is Carbomedtherapy (Carbon Dioxide Therapy)?

The carbon dioxide therapy is called Carbomedtherapy for diseases, and carboxytherapy for aesthetics. The CDT consists of transcutaneous injections of carbon dioxide. This technic was first practiced, in 1932, by Dr Barrieu, at Royat-Chamalières, France. Initially the indications were purely vascular especially for Raynaud's syndrome, arteriopathy of the lower limbs, leg ulcers, and of course, in the care of the diabetic foot.

What are the benefits of Carbomedtherapy?

• On the vascular level: An improvement for faster healing of the wounds and improvement of a walking perimeter.

. On the neurological level: Repair of vasa nervorum leads to neurological regeneration which allows a reduction or even disappearance of pain, tingling and numbness.

• Prevent the onset of other complications as well as the obesity related issues: kidney failure and hypertension.

• Decrease or even disappearance of the reported disorders thereby improving considerably the quality of life.

• Better static balance thereby allowing the return to ambulation, thus increasing the autonomy.

• Carbomed therapy sessions allow gradually the recovery of plantar sensitivity, the best prevention of foot wounds, thereby reducing the rate of amputation.

Carbon Dioxide Therapy indications for diabetics

Diabetic foot: We have two separate tables:

1) Patients with wounds.

2) Patients without wounds, but with vascular or neurological disease.Unfortunately, very often these aspects are simultaneously entangled.3) Diabesity

What are the Contraindications?

As a precaution, women who are pregnant. By obligation, patients with an imbalance of tares, especially respiratory and cardiac; Patients who had a recent acute stroke; Patients with active cancers and active viral infections; finally, with anaerobic germ infections. These situations can be reversed, however.

What are the side effects?

They are benign and above all reversible. There are superficial microhematomas at the injection points, which can sometimes follow a session especially if the patient is frankly de-coagulated. They disappear quickly and are not painful. There is no risk of gas embolism. The CO₂ pressures delivered by this machine are adjusted to avoid this problem even during accidental injection. The risks of infection should not exist. It is a simple matter of hygiene.

How to inject?

We use a device called CDT EVOLUTION. This device delivers heated carbon dioxide during the injections through disposable accessories: 13 mm and 30 G mesotherapy needles, and sterile tubing. The device being preprogrammed, we use the vascular program, the one which delivers 80cc of CO_2 per minute. The injections are transcutaneous and avoid well the vessels. We inject the surface of the 2 lower limbs, from the Scarpa triangle, around and on the wounds, and in the upper limbs in case of neuropathy. It is an outpatient practice. The rhythm of the sessions will depend on the severity of the case: once a week, bimonthly, or monthly

How does it work?

Hemoglobin molecules have 4 oxygen molecules at saturation. When we inject carbon dioxide, an exchange takes place between these oxygen molecules and those of CO₂. This phenomenon is described as BOHR effect (Fig. 1). We were able to record the instant nature of this exchange, by measuring PCO₂ and PO₂, during a CO₂ injection. What we found was that the PCO₂ measurement curve has not been changed while the PO₂ curve recorded an elevation.



Figure 1: Otherwise, CO_2 acts as a vasodilator on the precapillary sphincters, transforming silent zones into functional vascular zones. This is what we call false angiogenesis. This action is perpetuated by the repetition of the sessions by a real angiogenesis. So, there is an influx of blood. At the cellular level, exchanges become more important.

Evolution under Carbon Dioxide Therapy treatment

The evolution under the Carbon Dioxide Therapy treatment follows a scheme described below:

At the neurological level:

In the first place, the tingling disappears then the cramps--we believe that the correction of the Vit D3 rate is not unrelated to this. The pain gradually decreases as the Carbon Dioxide Therapy sessions progress. It is imperative to obtain a normal HbA1c level from the patient. Hyperglycemia is a real obstacle to healing by maintaining the perpetual attack of the nerves.

The second parameter is ambulation, the resumption of which remains difficult when physical activity no longer exists. Exercises performed by a third party to combat stiffness and muscle atrophy are necessary. The use of a wheeled walker allows confidence to be restored for walking autonomy. We consider the psychological problem linked to the fear that has settled in these patients with multiple histories of falls without counting the effects of the analgesic therapeutic withdrawal that we set up from the start of treatment.

The recovery of especially plantar sensitivity is done from top to bottom from the Scarpa triangle to the sole of the foot. It manifests itself by the appearance of pain during the injections made during the different Carbon Dioxide Therapy sessions.

• For carpal tunnel lesions, disappearance of pain and numbness allowing functional recovery.

Before starting the Carbon Dioxide Therapy treatment sessions, an ENMG of the four limbs is performed by an independent neurologist chosen by the patient. The control is done only after 12 to 24 sessions.

. At the vascular level:

Carbomedtherapy significantly improves vascularity. It repels ischemia and distinguishes necrotic from viable areas. We do not remove the necrosis so as not to deepen the lesions and thus obtain a well vascularized floor.

In conclusion, the Carbomedtherapy is a simple, safe, and efficient technique. Due to its learning, it is within the reach of any interested doctor. It is carried out externally, which reduces the cost of treatment. It is also within the reach of all patients.

References

- 1. Diabetic Foot Conference abstracts (2017).
- 2. Boudjenah N (2016) Diabetes and its Complications. Georgia World Congress Center, Atlanta, USA.
- 3. Boudjenah N (2016) Introduction of Carbomedtherapy Endocrine Practice. Jacksonville 22: 16.
- 4. Boudjenah A (2013) Diabetic feet: contribution of Carbomedtherapy. Diab Metab 39: A99.
- 5. Boudjenah N (2020) Diabetic Foot in Algeria. Int J Endocrinol Metab Disord 6(1).
- 6. Boudjenah N (2016) Introduction of Carbomedtherapy. Endocrine Practice. Pro Quest 22.
- Boudjenah N (2020) Advocacy for Carbomedtherapy (Carbon Dioxide Therapy) in the Treatment of Diabetic Neuropathy. Int J Endocrinol Metab Disord 6(2).
- Boudjenah N (2021) Diabetic Foot in Algeria Gangrene of the Extremities during COVID 19. J Endo Metabol Res 2(1):1-5.
- Boudjenah N (2021) Diabetic Foot in Algeria The Debridement of Wounds – our Attitude. Am J Biomed Sci & Res 13(5).
- 10. Boudjenah N (2021) Diabetic Foot in Algeria Illustration II.
- Nadia Boudjenah. Diabetic Foot in Algeria Illustration III Gangrene of the Extremities in Covid 19. Am J Biomed Sci & Res. 2021 - 14(1). AJBSR.MS.ID.001949. DOI: 10.34297/AJBSR.2021.14.001949.

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more www.auctoresonline.org/journals/archives-of-medical-case-reports-and-case-study



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here: Submit Manuscript

DOI:10.31579/2692-9392/137